In late 2020, after circulating for almost a year in the human population, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibited a major step change in its …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of
deaths and substantial morbidity worldwide. Intense scientific effort to understand the …

Continuous evolution of Omicron has led to a rapid and simultaneous emergence of
numerous variants that display growth advantages over BA. 5 (ref.). Despite their divergent …

Abstract Since SARS-CoV-2 BA. 5 (Omicron) emerged and spread in 2022, Omicron
lineages have markedly diversified. Here we review the evolutionary trajectories and …

Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …

Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, there have been
a few variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one of …

Recently, the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron
variant (B. 1.1. 529) was first identified in Botswana in November 2021. It was first reported …

We address whether T cell responses induced by different vaccine platforms (mRNA-1273,
BNT162b2, Ad26. COV2. S, and NVX-CoV2373) cross-recognize early SARS-CoV-2 …

The emergence of the SARS-CoV-2 variant of concern Omicron (Pango lineage B. 1.1. 529),
first identified in Botswana and South Africa, may compromise vaccine effectiveness and …

Abstract The SARS-CoV-2 B. 1.1. 529 (Omicron) variant contains 15 mutations of the
receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies …